Ludwig Enter Stock Price, News & Analysis

Summary not available.

Ludwig Enterprises, Inc. (OTC:LUDG) has unveiled its marketing strategy for the new nutraceutical, NuGenea, aimed at combating chronic inflammation—a key contributor to major illnesses like cancer and heart disease. Formulated with 20 scientifically validated ingredients, NuGenea represents a significant advancement in health and wellness. Chief Marketing Officer, Luke Fannon, announced a multifaceted approach, targeting both consumers and healthcare professionals through digital advertising and retail placements. Pre-orders are available for interested consumers. The company leverages proprietary mRNA genomic technology through its subsidiary, Precision Genomics, paving the way for early disease detection and personalized treatment options, potentially transforming healthcare.

Ludwig Enterprises, Inc. (OTC PINK:LUDG) announced the upcoming launch of its nutraceutical NuGenea™, designed to combat chronic inflammation. This product is formulated with 20 scientifically tested ingredients that may impact mRNA biomarkers linked to inflammation, as highlighted by creator Dr. Marvin S. Hausman MD. The World Health Organization estimates that 50% to 60% of global deaths are linked to chronic inflammation-related diseases. Ludwig's subsidiary Precision Genomics developed the mRNA Inflammatory Index™, a tool for monitoring 48 mRNA biomarkers of inflammation. NuGenea will be sold directly to consumers through an upcoming website. The company aims to transform healthcare with its genomic technology, potentially preventing serious health issues and reducing costs in the healthcare sector. For more information, visit Ludwig's website.

Ludwig Enterprises, Inc. (OTC PINK:LUDG) is advancing personalized healthcare through its subsidiary, Precision Genomics, with an innovative mRNA Inflammatory Index™. This technology, utilizing a simple cheek swab, measures 48 mRNA biomarkers to detect early-stage diseases and inflammation. The company is conducting an IRB-approved clinical study focused on early detection of bladder cancer. By offering potential early diagnosis, this mRNA-based approach could transform disease management and reduce healthcare costs. Ludwig's genetic technology positions it to significantly impact the healthcare industry with implications for chronic illness prevention and personalized treatments.

Ludwig Enterprises, Inc. (OTC PINK:LUDG) has entered into a partnership with Summit Bancorp to facilitate its cross-listing on the Canadian Stock Exchange (CSE). This move aims to attract a broader investor base. The company's subsidiary, Precision Genomics, is developing an mRNA Inflammatory Index (patent pending), which tracks 48 inflammation biomarkers, potentially transforming the management of chronic diseases. Ludwig's upcoming nutraceutical, NuGenea (patent pending), set for launch in Q2 2023, includes 20 ingredients intended to manage inflammation and decrease chronic disease risk. The innovations may significantly impact the healthcare sector.

Ludwig Enterprises, Inc. (OTC:LUDG) announced plans to file a Non-Offering Prospectus to facilitate its listing on the Canadian Stock Exchange in the second quarter of 2023. The company, along with its subsidiary Precision Genomics, developed a genomic mRNA microarray assay that evaluates 48 biomarkers related to chronic inflammation, with potential applications in managing various diseases, including cancer and diabetes. Ludwig's launch of the nutraceutical product NuGenea is also scheduled for the same quarter. The global mRNA therapeutics market is projected to reach $39.9 billion, highlighting significant growth opportunities for Ludwig in healthcare.

Ludwig Enterprises, Inc. is exploring growth opportunities through potential partnerships in nutraceutical products and a diabetes clinical study leveraging its proprietary mRNA Inflammatory Index. Discussions are ongoing with a foreign developer to sell their products in the U.S., aiming to capitalize on the 8.9% annual growth in the U.S. nutraceutical market. The company has collected over 1,700 samples for research on diabetes and related diseases. Ludwig's forward-looking statements emphasize the potential for increased revenue and improved health outcomes, although they acknowledge inherent risks in achieving these goals.

Ludwig Enterprises is generating significant clinical interest in its patent-pending mRNA Inflammatory Index™, which measures inflammatory biomarkers linked to chronic diseases like cancer and diabetes. The company has tested over 1,700 samples and receives over 100 new samples monthly from 28 clinics. The global mRNA therapeutics market is projected to reach $39.9 billion by 2030, driven by increasing chronic disease prevalence. Ludwig's research shows promising early results in identifying genetic differences in certain cancers. The company has IRB approval for bladder cancer studies and aims to enhance patient outcomes through its innovative genomic technology.

Ludwig Enterprises, Inc. (OTC PINK:LUDG) has announced the upcoming launch of its nutraceutical product, NuGenea, aimed at reducing chronic inflammation. Formulated with 20 carefully selected ingredients, NuGenea targets biomarkers linked to inflammation. Chief Medical Officer Dr. Marvin S. Hausman emphasized that chronic inflammation contributes to 50% of global deaths, and NuGenea could represent a significant advance in preventative health. The product is slated for sale through Amazon Prime and the company's website in Q2 2023. Ludwig Enterprises continues to innovate with its mRNA genomic technology, exploring new avenues in healthcare.